<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">37348646</PMID><DateCompleted><Year>2023</Year><Month>07</Month><Day>31</Day></DateCompleted><DateRevised><Year>2023</Year><Month>07</Month><Day>31</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1879-2618</ISSN><JournalIssue CitedMedium="Internet"><Volume>1868</Volume><Issue>9</Issue><PubDate><Year>2023</Year><Month>Sep</Month></PubDate></JournalIssue><Title>Biochimica et biophysica acta. Molecular and cell biology of lipids</Title><ISOAbbreviation>Biochim Biophys Acta Mol Cell Biol Lipids</ISOAbbreviation></Journal><ArticleTitle>SPTLC1 p.Leu38Arg, a novel mutation associated with childhood ALS.</ArticleTitle><Pagination><StartPage>159359</StartPage><MedlinePgn>159359</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.bbalip.2023.159359</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S1388-1981(23)00083-5</ELocationID><Abstract><AbstractText>Amyotrophic lateral sclerosis (ALS) is a progressive and fatal neuromuscular disease. Recently, several gain-of-function mutations in SPTLC1 were associated with juvenile ALS. SPTLC1 encodes for a subunit of the serine-palmitoyltransferase (SPT) - the rate-limiting enzyme in the de novo synthesis of sphingolipids (SL). SPT activity, and thus SL de novo synthesis, is tightly controlled by a homeostatic feedback mechanism mediated by ORMDL proteins. Here we report a novel SPTLC1p.L38R mutation in a young Chinese girl with a signature of juvenile ALS. The patient presented with muscular weakness and atrophy, tongue tremor and fasciculation, breathing problems and positive pyramidal signs. All SPTLC1-ALS mutations including the SPTLC1 p.L38R are located within a single membrane-spanning domain of the protein and impede the interaction with the regulatory ORMDL subunit of SPT. Pertinent to the altered homeostatic control, lipid analysis showed overall increased SL levels in the patient plasma. An increased SPT activity and SL de novo synthesis was confirmed in p.L38R expressing HEK293 cells. Particularily dihydro-sphingolipids (dhSL) were signficantly increased in patient plasma and p.L38R mutant expressing cells. Increased dhSL formation has been previously linked to neurotoxicity and may be involved in the pathomechanism of SPTLC1-ALS mutations.</AbstractText><CopyrightInformation>Copyright &#xa9; 2023. Published by Elsevier B.V.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Lone</LastName><ForeName>Museer A</ForeName><Initials>MA</Initials><AffiliationInfo><Affiliation>Institute for Clinical Chemistry, University Hospital and University of Z&#xfc;rich, Z&#xfc;rich, Switzerland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zeng</LastName><ForeName>Sen</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Neurology, The Third Xiangya Hospital, Central South University, Changsha, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bourquin</LastName><ForeName>Florence</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Institute for Biochemistry, University of Z&#xfc;rich; Z&#xfc;rich, Switzerland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>Mengli</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Neurology, The Third Xiangya Hospital, Central South University, Changsha, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Huang</LastName><ForeName>Shunxiang</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Neurology, The Third Xiangya Hospital, Central South University, Changsha, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lin</LastName><ForeName>Zhiqiang</ForeName><Initials>Z</Initials><AffiliationInfo><Affiliation>Department of Neurology, The Third Xiangya Hospital, Central South University, Changsha, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tang</LastName><ForeName>Beisha</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>National Clinical Research Center for Geriatric Disorders, Central South University, Changsha, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhang</LastName><ForeName>Ruxu</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Department of Neurology, The Third Xiangya Hospital, Central South University, Changsha, China. Electronic address: zhangruxu@vip.163.com.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hornemann</LastName><ForeName>Thorsten</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Institute for Clinical Chemistry, University Hospital and University of Z&#xfc;rich, Z&#xfc;rich, Switzerland. Electronic address: thorsten.hornemann@usz.ch.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2023</Year><Month>06</Month><Day>20</Day></ArticleDate></Article><MedlineJournalInfo><Country>Netherlands</Country><MedlineTA>Biochim Biophys Acta Mol Cell Biol Lipids</MedlineTA><NlmUniqueID>101731727</NlmUniqueID><ISSNLinking>1388-1981</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D013107">Sphingolipids</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 2.3.1.50</RegistryNumber><NameOfSubstance UI="D051102">Serine C-Palmitoyltransferase</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 2.3.1.50</RegistryNumber><NameOfSubstance UI="C487784">SPTLC1 protein, human</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002648" MajorTopicYN="N">Child</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000690" MajorTopicYN="Y">Amyotrophic Lateral Sclerosis</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D057809" MajorTopicYN="N">HEK293 Cells</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013107" MajorTopicYN="N">Sphingolipids</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009154" MajorTopicYN="N">Mutation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051102" MajorTopicYN="N">Serine C-Palmitoyltransferase</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Hereditary sensory and autonomic neuropathy type 1A (HSAN 1A)</Keyword><Keyword MajorTopicYN="N">Juvenile amyotrophic lateral sclerosis (jALS)</Keyword><Keyword MajorTopicYN="N">Serine-palmitoyltransferase (SPT)</Keyword></KeywordList><CoiStatement>Declaration of competing interest The authors report no competing interests.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2023</Year><Month>3</Month><Day>28</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2023</Year><Month>5</Month><Day>27</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2023</Year><Month>6</Month><Day>12</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>7</Month><Day>31</Day><Hour>6</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>6</Month><Day>23</Day><Hour>1</Hour><Minute>10</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>6</Month><Day>22</Day><Hour>19</Hour><Minute>13</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">37348646</ArticleId><ArticleId IdType="doi">10.1016/j.bbalip.2023.159359</ArticleId><ArticleId IdType="pii">S1388-1981(23)00083-5</ArticleId></ArticleIdList></PubmedData></PubmedArticle></PubmedArticleSet>